Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R) designed for the treatment of cancers.Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.
This page contains content from the copyrighted Wikipedia article "Ganitumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.